Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;1(2):29-34.
doi: 10.4103/2231-0770.90913.

Tissue plasminogen activator versus heparin for locking dialysis catheters: A systematic review

Belal M Firwana  1 , Rim Hasan, Mazen Ferwana, Joseph Varon, Aaron Stern, Umesh Gidwani
Affiliations

Tissue plasminogen activator versus heparin for locking dialysis catheters: A systematic review

Belal M Firwana et al. Avicenna J Med. 2011 Oct.

Abstract

Background and objectives: Hemodialysis catheters are commonly used when renal replacement therapy is initiated. These catheters have significant complications. Among "locking" solutions used in an attempt to decrease these complications is recombinant tissue plasminogen activator (rt-PA). This systematic review is to determine the efficacy of rt-PA versus heparin, the standard of care.

Materials and methods: A systematic review of randomized controlled trials studying rt-PA alone or rt-PA plus heparin versus heparin alone as locking agents for hemodialysis catheters, which included patients needed a temporary hemodialysis catheter for hemodialysis. We identified relevant trials through electronic databases and correspondence with experts. Two investigators independently reviewed potentially eligible trials and extracted data.

Results: Three trials met the inclusion criteria. One trial reported an improved catheter malfunctioning in patients using rt-PA plus heparin to lock catheters (20.0%) versus heparin alone (34.8%). Another trial reported higher blood flow rate in hemodialysis catheters in patients who received rt-PA (231.6 ± 12.4 mL/min) compared with those who received heparin (206.9 mL/min). The third trial reported formation and weight of clots which were decreased by half in rt-PA group versus heparin group.

Conclusions: In the few randomized trials that met our inclusion criteria, the use of rt-PA as a locking solution for hemodialysis catheters seems to be associated with fewer adverse events and catheter malfunctioning as compared with heparin. Our systematic review is limited by the few randomized trials addressing our question and the wide variety of outcome measures. Further prospective randomized trials are needed to confirm this conclusion.

Keywords: Anticoagulants; catheter; dialysis; hemodialysis; heparin; prophylaxis; tissue plasminogen activator.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Flow chart of the systematic review
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Collins AJ, Foley RN, Gilbertson DT, Chen SC. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol. 2009;4(Suppl 1):S5–11. - PubMed
    1. Allon M. Dialysis catheter-related bacteremia: Treatment and prophylaxis. Am J Kidney Dis. 2004;44:779–91. - PubMed
    1. Duncan ND, Singh S, Cairns TD, Clark M, El-Tayar A, Griffith M, et al. Tesio-Caths provide effective and safe long-term vascular access. Nephrol Dial Transplant. 2004;19:2816–22. - PubMed
    1. Suhocki PV, Conlon PJ, Jr, Knelson MH, Harland R, Schwab SJ. Silastic cuffed catheters for hemodialysis vascular access: Thrombolytic and mechanical correction of malfunction. Am J Kidney Dis. 1996;28:379–86. - PubMed
    1. Klouche K, Amigues L, Deleuze S, Beraud JJ, Canaud B. Complications, effects on dialysis dose, and survival of tunneled femoral dialysis catheters in acute renal failure. Am J Kidney Dis. 2007;49:99–108. - PubMed